FDA grants Barr permission to move forward with generic Razadyne
WASHINGTON The Food and Drug Administration has approved Barr’s generic version of Johnson & Johnson’s Razadyne ER capsules, according to an FDA bulletin that gave an approval date of Sept. 15.
The capsules, whose active ingredient is galantamine hydrobromide, are approved for treating Alzheimer?s disease. They are available in 8 mg, 16 mg and 24 mg doses.
As the first company to file an application for a generic version of Razadyne ER, Barr Laboratories will receive 180 days of market exclusivity.
Sandoz and KV Pharma have also filed applications for generic versions of the drug, according to J&J’s annual report.
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.